Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration

Table 1 Experimental design

	Group
Analysis time point (Immunohistochemistry)	rAAV2/7-WT α SYN		rAAV2/7-eGFP		rAAV2/7-WT α SYN
	(4E + 11 GC/ml)		(4E + 11 GC/ml)		(1E + 11 GC/ml)
	high α -SYN dose				low α -SYN dose
	parkin ^+/+	parkin ^−/−	parkin ^+/+	parkin ^−/−	parkin ^+/+	parkin ^−/−
1 week	n = 4	n = 4			n = 2	n = 3
4 weeks	n = 15	n = 16	n = 5	n = 6	n = 10	n = 13
8 weeks					n = 6	n = 5
16 weeks					n = 6	n = 6

Adult 2 to 4-month-old parkin^+/+ and parkin^−/− mice were stereotactically injected in the right SN with 2 μl of rAAV2/7-WT α-SYN vector at a titer of 4E + 11 GC/ml (high α-SYN dose) or 1E + 11 GC/ml (low α-SYN dose) or rAAV2/7-eGFP vector at a titer of 4E + 11 GC/ml. At the mentioned time points after injection, animals were perfused for immunohistochemical analysis.

ISSN: 1750-1326